主讲人: 胡奇 特聘研究员
时间: 2026年11月20日10:30-11:30
地点: 琳恩图书馆111报告厅
题 目:Small Molecule Drug Development: From Enzyme Inhibitors to Enzyme Recruiters(小分子药物研发:从酶抑制剂到酶招募剂)
主 讲:胡奇 特聘研究员
时 间:2026年11月20日(周五)10:30-11:30
地 点:琳恩图书馆111报告厅
报告摘要:
Enzyme-targeted small-molecule drug discovery has expanded beyond classical direct inhibition, with proximity-based functional modulation emerging as a new direction. Using the classical inhibition approach, we identified a potent noncovalent SARS-CoV-2 3CLpro inhibitor, WU-04, via DNA-encoded library screening. This compound, developed as Mprosevir, exhibits broad anti-coronavirus activity and has received conditional marketing approval in China for COVID-19 treatment. Applying the proximity-based strategy to the canonical RAS-RAF-MEK-ERK pathway, we recruited phosphatases to inactivate oncogenic BRAF/MEK, including drug-resistant BRAF splicing variants, and built a depalmitoylase-tethered system to modulate RAS palmitoylation, leading to the discovery of novel palmitoyltransferase inhibitors. These strategies diversify small-molecule intervention strategies and expand druggable target space.
个人简介:
Dr. Qi Hu received his bachelor’s degree in pharmaceutical sciences and master’s degree in medicinal chemistry from the School of Pharmaceutical Sciences, Peking University, Beijing, China. He then joined the School of Life Sciences, Tsinghua University and received his doctoral degree in biology in 2014. In 2015, he joined Prof. Kevan Shokat’s lab in the University of California, San Francisco for postdoctoral training. Dr. Hu was awarded the prestigious Damon Runyon Postdoctoral Fellowship in 2015. Since 2019, Dr. Hu has been a Principal Investigator in the School of Life Sciences at Westlake University.